Howard,
You are hallucinating!! I don't know where you got your numbers and I certainly don't know whether your "source" is accurate, but even if they have sold 8 million in strep a tests alone, there is no way it will result in earings of 20-30 million this quarter, let alone this year. For the first 3 quarters of fy 1997, ending in 12-96, they had total revenues of approx. $29,676,000. I don't know how much of their 3rd quarter sales were due to strep alone, but I'm sure it was a substantial percentage of their 3rd quarter sales revenue (excluding Glaxo research reimbursement) of approx $11,727,000.
I don't understand your math at all- they have approx 22,374,000
shares outstanding according to 3rd qtr earnings release. Through the first 3 quarters of fy 97, they have made (net profit) approx. $2,206,000, which works out to about $0.10 per share so far for the first 3 quarters. How do you get 20-30 million in "earnings" this quarter( I think you must mean "revenues", which is still too high), how do you get 6-16 million in "net profit" this quarter, and lastly how do you get $.20-.30 per share this quarter??? Even if your "source" is correct, aren't you presuming that their strep sales were equally as strong during Jan and Feb as well???
I seriously doubt if your "source" knows what he is talking about in terms of revenue from strep sales. Don't get me wrong, I am a big Quidel supporter and I think they will report an excellent quarter. Even if your numbers are sound, there is no way they add up to anywhere near your projections. I would consider it a great quarter if they reach 15 million in revenue from all sources (glaxo included) in the 4th quarter and make $.10-.12 cents per share for the quarter, giving them about $.20-.22 per share for fy 97, which would greatly exceed forecasts for FY 97 of $.14 and which would actually be right on target for next year (FY 98)!!!!!!!
Hoping you are right and I am wrong as hell,
BOB
P.S. Did these figures come from ANALYST X????? |
